A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden

Acta Ophthalmologica Scandinavica

Volumn 84, Issue 1, 2006, Pages 74-83

  Lindblom, Bertil ^a   Nordmann, Jean Philippe ^b   Sellem, Eric ^c   Chen, Enping ^d   Gold, R ^e   Polland, Werner ^f   Williamson, W ^g   Buchholz, Patricia ^h   Walt, John G ⁱ   Groleau, Danielle ^h   Curry, Alistair ^j   Evans, Stacy J ^k  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^c Centre Ophtalmologique Kleber   (France)

^d ST ERIK S EYE HOSPITAL   (Sweden)

^e Raincy Montfermeil Hospital   (France)

^f Eye Clinic   (Sweden)

^g University Hospital   (France)

^h ALLERGAN PLC   (United States)

ⁱ ALLERGAN INC   (United States)

^j IQVIA   (United States)

^k Quintiles UK Ltd ^*  (United States)

more..

Author keywords

Cost effectiveness; Glaucoma; Health care costs; Health expenditures; Intraocular pressure; Ocular hypertension; Treatment costs

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; ECONOMIC EVALUATION; FEMALE; FRANCE; GLAUCOMA SURGERY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; SWEDEN;

AGED; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FRANCE; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMOLOGIC SURGICAL PROCEDURES; RETROSPECTIVE STUDIES; SWEDEN;

EID: 33644777689     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2005.00560.x     Document Type: Article

References (31)

1. Akademiska Sjukhuset (2002): Prislista 2002. Sluten och Öppen vård. [Price list for 2002 for Akademiska University Hospital.]
2. Bonomi L, Marchini G, Marraffa M & Morbio R (2001): The relationship between intraocular pressure and glaucoma in a defined population. Data from the Egna-Neumarkt Glaucoma Study. Ophthalmologica 215: 34-38.
3. Caisse Nationale d'Assurance Maladie (2002): Conventions et tariffs. http://www.cnamts.fr. [Accessed November 2002.]
4. Coffey M, Reidy A, Wormald R, Xian WX, Wright L & Courtney P (1993): Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 77: 17-21.
5. Coyle D & Drummond M (1995): The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmaco-economics 7: 484-489.
6. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE & de Jong PT (1993): The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam Study. Ophthalmology 101: 1851-1855.
7. European Glaucoma Society (EGS) (1998): 1998 Terminology and Guidelines for Glaucoma. Savona: Editrice DOGMA.
8. FASS (2002): Läkemedelsfakta. http://www.fass.se/LIF/produktfakta/ produktfakta.jsp. [Accessed November 2002.]
9. Federation of County Councils (1999): Cost per Patient, Bed-day, Physician Visit etc. in 1996. Stockholm: Federation of County Councils.
10. Glaucoma Laser Trial (GLT) & Glaucoma Laser Trial Follow-up Study (1995): 7. Results. Am J Ophthalmol 120: 718-731.
11. Henriksson F, Fredrikson S & Jönsson B (2000): Costs, quality of life and disease severity in multiple sclerosis - a population-based cross-sectional study in Sweden. Working paper no. 361. SSE/EFI Working Paper Series in Economics and Finance. Stockholm: Stockholm School of Economics.
12. Jönsson B & Kriegelstein G (1998): Primary open-angle glaucoma. Differences in international treatment patterns and costs. Oxford: Isis Medical Media.
13. Kobelt G, Jönsson L, Gerdtham U & Kriegelstein GK (1998): Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 236: 811-821.
14. Kobelt-Nguyen G, Gerdtham U & Alm A (1998): Costs of treating primary open-angle glaucoma and ocular hypertension: A retrospective, observational 2-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 7: 95-104.
15. Kocur I & Resnikoff S (2002): Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 86: 716-722.
16. Kroese M, Burton H, Vardy S, Rimmer T & McCarter D (2002): Prevalence of primary open-angle glaucoma in general ophthalmology practice in the United Kingdom. Br J Ophthalmol 86: 978-980.
17. Lee PP, Walt JG, Doyle JJ et al. (2005): A multicentre, retrospective pilot study of resource utilization and costs associated with severity of disease in glaucoma. Ophthalmology. In press.
18. Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Casciano JP, Doyle JJ & Evans SJ (2002): Categorizing the progression of glaucoma from pre-diagnosis to end-stage disease by a novel six-point staging system. [Abstract 2160.] 2002 Annual Meeting Abstract and Program Planner. Association for Research in Vision and Ophthalmology. http://www.arvo.org.
19. Musch DC, Lichter PR, Guire KE, Standardi CL & the CIGTS Study Group (1999): The Collaborative Initial Glaucoma Treatment Study. Ophthalmology 106: 653-662.
20. Nomenclature Générale des Actes Professi-onnels (2002): Mise à Jour 1-2002. Paris: Union des Casses Nationales de Sécurité Sociale (UCANSS).
21. Norrlands Universitetssjukhus (2002): Prislista år 2002 för Norrlands Universitetssjukhus. [Price list for 2002 from Norrland University Hospital.]
22. Oostenbrink JB, Rutten-van Mölken MPMH & Opdenoordt TS (1999): The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in the Netherlands: An observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 98: 285-299.
23. Oostenbrink JB, Rutten-van Mölken MPMH & Sluyter-Opdenoordt TS (2001): Resource use and costs of patients with glaucoma or ocular hypertension: A 1-year study based on retrospective chart review in the Netherlands. J Glaucoma 10: 184-191.
24. Organisation for Economic Co-operation and Development (OECD) (2003): Exchange rates August 2000, national currency to Euro. http://www.oecd.org/dataoecd/55/62/2487525.pdf. [Accessed January 2003.]
25. Programme de Médicalisation des Systèmes d'Information (2002): Coûts de reference. http://www.le-pmsi.fr. [Accessed November 2002.]
26. Quigley HA (1996): Number of people with glaucoma worldwide. Br J Ophthalmol 80: 389-393.
27. Södra Sjukvårdsregionen (2002): Prislista för Södra Sjukvårdsregionen 2002. [Price list for 2002 from the southern health care region in Sweden.] http://www.srvn.org/ prislista.htm. [Accessed November 2002.]
28. Strutton DR & Walt JG (2004): Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 13: 221-226.
29. Traverso CE, Gandolfi SA, Kelly SP et al. (2003): Estimation of resource utilization associated with glaucoma disease progression in a multinational retrospective study in Europe. [Abstract.] Presented at the American Academy of Ophthalmology 2003 Annual Meeting, November 15-18, 2003, Anaheim, California, USA.
30. Västra Sjukvårdsregionen (2002): Utomlänspriser 2002. För vårdtjänster enligt samverkansavtal om hälso- och sjukvård inom Västra Sjukvårdsregionen. [Price list for 2002 from the western health care region in Sweden.]
31. Vidal (2002): L'information de référence sur les produits de santé. http://www.vidal.fr/recherchemedicament.asp. [Accessed November 2002.]